{"gene":"APOA2","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1972,"finding":"ApoA-II (apoLp-Gln-II) was isolated from human HDL and its complete amino acid sequence determined: it is composed of two identical polypeptide chains of 77 amino acids each, connected by a single disulfide bridge at position 6, with pyrrolidone carboxylic acid as the N-terminal residue and glutamine as the C-terminal residue, giving a minimum molecular weight of 17,380.","method":"Protein isolation and amino acid sequencing","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — direct protein isolation and complete sequence determination, foundational structural characterization","pmids":["4338591"],"is_preprint":false},{"year":1978,"finding":"ApoA-II forms a mixed disulfide complex with apoE (apoprotein E–A-II complex) in human plasma lipoproteins; this complex was isolated and characterized, and identified in a high-density lipoprotein subfraction, demonstrating that apoA-II participates in inter-apolipoprotein disulfide bonding.","method":"Protein isolation, characterization of mixed disulfide complex, lipoprotein subfraction identification","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct biochemical isolation and characterization of the disulfide complex","pmids":["210174"],"is_preprint":false},{"year":1984,"finding":"The cDNA sequence of human apoA-II was determined, revealing that prepro-apoA-II contains an 18-amino-acid signal peptide and a classical 5-amino-acid propeptide, establishing the biosynthetic precursor structure of the protein.","method":"cDNA cloning and nucleotide sequencing, mRNA abundance measurement","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 — direct cDNA sequencing establishing prepro-protein structure","pmids":["6328445"],"is_preprint":false},{"year":1986,"finding":"LCAT mass, LCAT activity, and cholesteryl ester transfer (CET) activity in human plasma are predominantly (69–81%) associated with Lp(A-I without A-II) HDL particles rather than Lp(A-I with A-II) particles, demonstrating that the presence of apoA-II on HDL negatively influences the association of LCAT and CET activities with those particles.","method":"Immunoaffinity isolation of HDL subfractions, gel filtration, activity assays for LCAT and CET","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1–2 — direct biochemical fractionation with functional activity measurements in multiple subjects","pmids":["3104518"],"is_preprint":false},{"year":2001,"finding":"ABCA1 mediates cholesterol and phospholipid efflux using apoA-II as an acceptor apolipoprotein; apoA-II binds to ABCA1-expressing cells with a Kd of 0.58 µg/mL (similar affinity to apoA-I), demonstrating that ABCA1-mediated lipid efflux and apolipoprotein binding is not specific to apoA-I but extends to apoA-II and other exchangeable apolipoproteins containing amphipathic helical domains.","method":"Stably transfected HeLa cells expressing ABCA1-GFP, cholesterol and phospholipid efflux assays, specific binding assays","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro reconstitution in transfected cells with binding constants and efflux quantification","pmids":["11162594"],"is_preprint":false},{"year":2005,"finding":"TDP-43 binds the (GU)16 repeat tract at the intron 2/exon 3 junction of the APOA2 pre-mRNA and acts as a splicing silencer; depletion of TDP-43 by siRNA renders exon 3 inclusion constitutive, overriding the need for exonic (ASF/SF2, SC35-dependent ESE) and intronic (SRp40/SRp55-dependent) splicing enhancers. Additionally, hnRNPH1 binds a G-rich element in intron 2 to inhibit exon 3 splicing, while SRp40 and SRp55 bind a purine-rich region in intron 3 to promote inclusion.","method":"siRNA knockdown of TDP-43, in vitro splicing assays, UV cross-linking/immunoprecipitation, mutagenesis of cis-elements","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 — siRNA knockdown with constitutive splicing phenotype, multiple orthogonal methods including mutagenesis and factor-binding assays","pmids":["16254078"],"is_preprint":false},{"year":2018,"finding":"The APOA2 -265T>C (rs5082) promoter polymorphism interacts with saturated fatty acid (SFA) intake to alter DNA methylation at CpG site cg04436964 in the APOA2 regulatory region; CC genotype carriers on a high-SFA diet show differential methylation at this site compared to TT carriers, and this is negatively correlated with APOA2 mRNA expression. CC carriers consuming high-SFA had lower APOA2 expression than TT carriers. Metabolomic analysis linked these genotype-specific methylation differences to alterations in tryptophan and branched-chain amino acid (BCAA) metabolic pathways.","method":"Epigenome-wide scan (DNA methylation), transcriptomic analysis of APOA2 mRNA, metabolomics, validated in three independent cohorts","journal":"The American journal of clinical nutrition","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (methylation, transcriptomics, metabolomics) replicated across three independent cohorts","pmids":["29901700"],"is_preprint":false},{"year":2024,"finding":"SAMD4B suppresses APOA2 mRNA stability via 2'-O-methylation modification at the C-terminus of APOA2 mRNA; reduced APOA2 protein levels resulting from this modification lead to decreased PD-L1 expression through a direct APOA2–PD-L1 interaction, thereby improving the tumor immune microenvironment in hepatocellular carcinoma.","method":"2'-O-methylation modification assay, multiplex immunofluorescence, single-cell RNA sequencing in PDX mouse models, protein interaction assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2–3 — novel epitranscriptomic mechanism with multiple supporting methods but single lab, complex multi-component pathway","pmids":["38886351"],"is_preprint":false},{"year":2025,"finding":"APOA2 impairs dendritic cell antigen presentation through the PPAR signaling pathway, contributing to an immunosuppressive tumor microenvironment in hepatocellular carcinoma; APOA2 expression was negatively correlated with MHC molecule expression on dendritic cells.","method":"Spatial transcriptomics, single-cell RNA sequencing, hdWGCNA, CellChat ligand-receptor interaction analysis, TCGA validation","journal":"Translational cancer research","confidence":"Low","confidence_rationale":"Tier 3–4 — computational/transcriptomic analysis, no direct in vitro or in vivo functional validation of APOA2 acting on DCs","pmids":["41158225"],"is_preprint":false},{"year":2026,"finding":"APOA2 overexpression in hepatocellular carcinoma cells promotes antiangiogenic drug resistance by upregulating TGF-β secretion; TGF-β in turn reduces VEGFR2 expression and induces endothelial-to-mesenchymal transition (EndoMT) in vascular endothelial cells, while simultaneously initiating fatty acid oxidation and increased free fatty acid uptake in cancer cells to stimulate proliferation. Pharmacological inhibition of TGF-β eliminated APOA2-mediated EndoMT and lipid metabolic reprogramming.","method":"APOA2 overexpression in HCC mouse models, whole transcriptome sequencing, proteomic analysis, TGF-β inhibition experiments","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo mouse model with overexpression, proteomic validation, and pharmacological rescue experiment","pmids":["41760604"],"is_preprint":false}],"current_model":"APOA2 encodes a homodimeric HDL apolipoprotein (two 77-aa chains linked by a disulfide at position 6, synthesized as a prepro-protein with signal and propeptide sequences) that acts as an ABCA1 lipid-efflux acceptor, forms mixed disulfides with apoE on HDL, inhibits LCAT and cholesteryl ester transfer activity on HDL particles, and undergoes TDP-43-dependent pre-mRNA splicing regulation; its promoter methylation and expression are modulated by saturated fat intake in a genotype-dependent manner, and emerging evidence indicates APOA2 protein participates in TGF-β-mediated endothelial-mesenchymal transition and lipid metabolic reprogramming in cancer contexts."},"narrative":{"teleology":[{"year":1972,"claim":"Determining the primary structure of apoA-II established it as a disulfide-linked homodimer of 77-residue chains, defining the fundamental architecture of the second major HDL apolipoprotein.","evidence":"Protein isolation from human HDL and complete amino acid sequencing","pmids":["4338591"],"confidence":"High","gaps":["No three-dimensional structure determined","Lipid-binding mechanism and amphipathic helix arrangement unresolved","Biological function of the disulfide linkage unknown"]},{"year":1978,"claim":"Discovery of a mixed apoE–apoA-II disulfide complex in plasma lipoproteins revealed that apoA-II participates in inter-apolipoprotein covalent interactions, suggesting it modulates HDL composition beyond simple structural scaffolding.","evidence":"Biochemical isolation and characterization of the disulfide complex from human plasma HDL subfractions","pmids":["210174"],"confidence":"High","gaps":["Functional consequence of apoE–apoA-II complex formation on lipoprotein metabolism unknown","Stoichiometry and regulation of complex formation not defined"]},{"year":1984,"claim":"cDNA cloning revealed that apoA-II is synthesized as a prepro-protein with an 18-aa signal peptide and a 5-aa propeptide, establishing its secretory biosynthetic pathway.","evidence":"cDNA cloning and nucleotide sequencing of human APOA2","pmids":["6328445"],"confidence":"High","gaps":["Propeptide cleavage protease not identified","Tissue-specific regulation of APOA2 transcription not characterized"]},{"year":1986,"claim":"Demonstration that LCAT and cholesteryl ester transfer activities preferentially associate with apoA-I-only HDL particles established apoA-II as a negative modulator of HDL cholesterol esterification and transfer, clarifying a long-debated functional distinction between HDL subclasses.","evidence":"Immunoaffinity fractionation of HDL subpopulations with LCAT and CET activity assays in human plasma","pmids":["3104518"],"confidence":"High","gaps":["Direct molecular mechanism by which apoA-II excludes LCAT/CET activity not elucidated","In vivo metabolic consequences of altered LCAT partitioning not tested"]},{"year":2001,"claim":"Showing that apoA-II binds ABCA1 with affinity comparable to apoA-I and mediates cholesterol/phospholipid efflux broadened the understanding of ABCA1 beyond apoA-I, positioning apoA-II as a physiological lipid acceptor in reverse cholesterol transport.","evidence":"Cholesterol and phospholipid efflux assays and specific binding measurements in ABCA1-GFP-transfected HeLa cells","pmids":["11162594"],"confidence":"High","gaps":["Relative in vivo contribution of apoA-II versus apoA-I to ABCA1-mediated efflux not quantified","Whether apoA-II-containing nascent HDL particles have distinct downstream fates is unknown"]},{"year":2005,"claim":"Identification of TDP-43 as a splicing silencer of APOA2 exon 3 uncovered a post-transcriptional control layer for apoA-II expression, showing that a ubiquitous RNA-binding protein governs alternative splicing of this liver-expressed gene.","evidence":"siRNA knockdown of TDP-43, in vitro splicing, UV cross-linking/immunoprecipitation, and cis-element mutagenesis","pmids":["16254078"],"confidence":"High","gaps":["Physiological signals that modulate TDP-43's splicing activity on APOA2 not identified","Consequences of exon 3 inclusion/skipping on apoA-II protein function not characterized"]},{"year":2018,"claim":"Demonstrating that the -265T>C promoter polymorphism interacts with saturated fat intake to alter CpG methylation and APOA2 expression provided a gene-environment epigenetic mechanism for inter-individual variation in apoA-II levels.","evidence":"Epigenome-wide methylation, transcriptomic, and metabolomic analyses replicated across three independent cohorts","pmids":["29901700"],"confidence":"High","gaps":["Causal direction of methylation–expression relationship not established by intervention","How altered apoA-II levels translate to downstream changes in tryptophan and BCAA metabolism is mechanistically undefined"]},{"year":2024,"claim":"Discovery that SAMD4B destabilizes APOA2 mRNA via 2'-O-methylation and that reduced apoA-II decreases PD-L1 through a direct protein interaction revealed an unexpected immunoregulatory role for apoA-II in the tumor microenvironment.","evidence":"2'-O-methylation assays, multiplex immunofluorescence, single-cell RNA-seq in PDX mouse models, and protein interaction assays in hepatocellular carcinoma","pmids":["38886351"],"confidence":"Medium","gaps":["Direct apoA-II–PD-L1 binding interface not structurally characterized","Specificity of the 2'-O-methylation mechanism to APOA2 versus other mRNAs not assessed","Independent replication in a second laboratory pending"]},{"year":2025,"claim":"Computational spatial transcriptomics linked APOA2 to impaired dendritic cell antigen presentation via PPAR signaling in HCC, but this remains a correlative observation without direct functional validation.","evidence":"Spatial transcriptomics, single-cell RNA-seq, hdWGCNA, and CellChat analysis in hepatocellular carcinoma tissues","pmids":["41158225"],"confidence":"Low","gaps":["No in vitro or in vivo functional experiment directly testing apoA-II's effect on dendritic cell MHC expression","PPAR pathway link is inferred computationally without pharmacological or genetic perturbation","Single study without independent cohort replication"]},{"year":2026,"claim":"In vivo overexpression showed that apoA-II drives antiangiogenic drug resistance in HCC by upregulating TGF-β, which induces endothelial-mesenchymal transition and lipid metabolic reprogramming, and TGF-β inhibition reverses these effects.","evidence":"APOA2 overexpression in mouse HCC models with whole transcriptome sequencing, proteomics, and pharmacological TGF-β inhibition","pmids":["41760604"],"confidence":"Medium","gaps":["Mechanism by which apoA-II upregulates TGF-β secretion is unknown","Whether this cancer-context role reflects a physiological function of apoA-II in non-malignant tissue is untested","Confirmation in patient-derived models or clinical samples needed"]},{"year":null,"claim":"The structural basis by which apoA-II modulates LCAT and CET activity on HDL, the physiological significance of the apoE–apoA-II disulfide complex, and whether apoA-II's newly described immunomodulatory and TGF-β-related activities in cancer operate through the same lipid-binding surfaces used in lipoprotein metabolism remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of lipid-bound apoA-II dimer","Relative in vivo contribution of apoA-II to reverse cholesterol transport versus apoA-I not quantified","Mechanistic link between apoA-II's lipid-binding properties and its cancer-associated signaling roles undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,3,4]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,4]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,4,6]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[9]}],"complexes":["HDL particle","apoE-apoA-II disulfide complex"],"partners":["APOE","ABCA1","TARDBP","PD-L1","TGFB1"],"other_free_text":[]},"mechanistic_narrative":"Apolipoprotein A-II is the second most abundant protein of high-density lipoproteins, synthesized as a prepro-protein (18-aa signal peptide plus 5-aa propeptide) that matures into a homodimer of two 77-residue chains linked by a Cys-6 disulfide bridge [PMID:4338591, PMID:6328445]. On HDL particles, apoA-II forms mixed disulfide complexes with apoE [PMID:210174], serves as an acceptor for ABCA1-mediated cholesterol and phospholipid efflux with nanomolar-range binding affinity [PMID:11162594], and restricts the association of LCAT and cholesteryl ester transfer activities to apoA-II-containing particles [PMID:3104518]. APOA2 pre-mRNA splicing is regulated by TDP-43, which silences exon 3 inclusion by binding a (GU)₁₆ intronic element, while promoter methylation at the -265T>C polymorphism modulates APOA2 expression in a saturated-fat-intake-dependent manner [PMID:16254078, PMID:29901700]. In hepatocellular carcinoma, APOA2 overexpression drives TGF-β-dependent endothelial-mesenchymal transition, lipid metabolic reprogramming, and antiangiogenic drug resistance, and APOA2 protein interacts with PD-L1 to modulate the tumor immune microenvironment [PMID:41760604, PMID:38886351]."},"prefetch_data":{"uniprot":{"accession":"P02652","full_name":"Apolipoprotein A-II","aliases":["Apolipoprotein A2"],"length_aa":100,"mass_kda":11.2,"function":"May stabilize HDL (high density lipoprotein) structure by its association with lipids, and affect the HDL metabolism","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P02652/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOA2","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOA2","total_profiled":1310},"omim":[{"mim_id":"621417","title":"APOLIPOPROTEIN A-II DEFICIENCY; APOA2D","url":"https://www.omim.org/entry/621417"},{"mim_id":"608862","title":"NAD(P)HX EPIMERASE; NAXE","url":"https://www.omim.org/entry/608862"},{"mim_id":"606945","title":"LOW DENSITY LIPOPROTEIN RECEPTOR; LDLR","url":"https://www.omim.org/entry/606945"},{"mim_id":"602491","title":"HYPERLIPIDEMIA, FAMILIAL COMBINED, 1; FCHL1","url":"https://www.omim.org/entry/602491"},{"mim_id":"600390","title":"UPSTREAM TRANSCRIPTION FACTOR 2, FOS-INTERACTING; USF2","url":"https://www.omim.org/entry/600390"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":33506.8}],"url":"https://www.proteinatlas.org/search/APOA2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P02652","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02652","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02652-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02652-F1-predicted_aligned_error_v6.png","plddt_mean":75.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOA2","jax_strain_url":"https://www.jax.org/strain/search?query=APOA2"},"sequence":{"accession":"P02652","fasta_url":"https://rest.uniprot.org/uniprotkb/P02652.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02652/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02652"}},"corpus_meta":[{"pmid":"19901143","id":"PMC_19901143","title":"APOA2, dietary fat, and body mass index: replication of a gene-diet interaction in 3 independent populations.","date":"2009","source":"Archives of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19901143","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20975728","id":"PMC_20975728","title":"Association between the APOA2 promoter polymorphism and body weight in Mediterranean and Asian populations: replication of a gene-saturated fat interaction.","date":"2010","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/20975728","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26365669","id":"PMC_26365669","title":"Interaction of dietary fat intake with APOA2, APOA5 and LEPR polymorphisms and its relationship with obesity and dyslipidemia in young subjects.","date":"2015","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/26365669","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11163832","id":"PMC_11163832","title":"Microsatellite DNA assays reveal an allelic imbalance in p16(Ink4), GALT, p53, and APOA2 loci in patients with endometriosis.","date":"2001","source":"Fertility and sterility","url":"https://pubmed.ncbi.nlm.nih.gov/11163832","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29901700","id":"PMC_29901700","title":"Epigenomics and metabolomics reveal the mechanism of the APOA2-saturated fat intake interaction affecting obesity.","date":"2018","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/29901700","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16274472","id":"PMC_16274472","title":"Mapping and characterization of the amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH.","date":"2005","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16274472","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12136239","id":"PMC_12136239","title":"Sequence polymorphism at the human apolipoprotein AII gene ( APOA2): unexpected deficit of variation in an African-American sample.","date":"2002","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12136239","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24382995","id":"PMC_24382995","title":"APOA2 Polymorphism in Relation to Obesity and Lipid Metabolism.","date":"2013","source":"Cholesterol","url":"https://pubmed.ncbi.nlm.nih.gov/24382995","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3136074","id":"PMC_3136074","title":"Regional chromosomal localisation of APOA2 to 1q21-1q23.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3136074","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25904114","id":"PMC_25904114","title":"APOA2 -256T>C polymorphism interacts with saturated fatty acids intake to affect anthropometric and hormonal variables in type 2 diabetic patients.","date":"2015","source":"Genes & nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/25904114","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3122561","id":"PMC_3122561","title":"Evidence for linkage of Charcot-Marie-Tooth neuropathy (CMT1) to apolipoprotein A2 (Apo-A2).","date":"1988","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3122561","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12119199","id":"PMC_12119199","title":"A candidate gene study in low HDL-cholesterol families provides evidence for the involvement of the APOA2 gene and the APOA1C3A4 gene cluster.","date":"2002","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/12119199","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14722362","id":"PMC_14722362","title":"Novel QTLs for HDL levels identified in mice by controlling for Apoa2 allelic effects: confirmation of a chromosome 6 locus in a congenic strain.","date":"2004","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/14722362","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19216768","id":"PMC_19216768","title":"Evaluating the association of common APOA2 variants with type 2 diabetes.","date":"2009","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19216768","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25606421","id":"PMC_25606421","title":"Evaluating the association of APOA2 polymorphism with insulin resistance in adolescents.","date":"2014","source":"Meta gene","url":"https://pubmed.ncbi.nlm.nih.gov/25606421","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2500391","id":"PMC_2500391","title":"The genes for apolipoprotein all (APOA2) and the Duffy blood group (FY) are linked on chromosome 1 in man.","date":"1989","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/2500391","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33674281","id":"PMC_33674281","title":"apoA2 correlates to gestational age with decreased apolipoproteins A2, C1, C3 and E in gestational diabetes.","date":"2021","source":"BMJ open diabetes research & care","url":"https://pubmed.ncbi.nlm.nih.gov/33674281","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38886351","id":"PMC_38886351","title":"Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38886351","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32120838","id":"PMC_32120838","title":"Association between the APOA2 rs3813627 Single Nucleotide Polymorphism and HDL and APOA1 Levels Through BMI.","date":"2020","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/32120838","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17485926","id":"PMC_17485926","title":"Quantitative trait locus analysis of plasma cholesterol levels and body weight by controlling the effects of the Apoa2 allele in mice.","date":"2007","source":"The Journal of veterinary medical science","url":"https://pubmed.ncbi.nlm.nih.gov/17485926","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37511084","id":"PMC_37511084","title":"APOA2: New Target for Molecular Hydrogen Therapy in Sepsis-Related Lung Injury Based on Proteomic and Genomic Analysis.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37511084","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35883173","id":"PMC_35883173","title":"Dietary acid load modifies the effects of ApoA2-265 T > C polymorphism on lipid profile and serum leptin and ghrelin levels among type 2 diabetic patients.","date":"2022","source":"BMC endocrine disorders","url":"https://pubmed.ncbi.nlm.nih.gov/35883173","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24004543","id":"PMC_24004543","title":"Novel polymorphisms of the APOA2 gene and its promoter region affect body traits in cattle.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/24004543","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38062157","id":"PMC_38062157","title":"CETP and APOA2 polymorphisms are associated with weight loss and healthy eating behavior changes in response to digital lifestyle modifications.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38062157","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34167597","id":"PMC_34167597","title":"ApoA2-256T > C polymorphism interacts with Healthy Eating Index, Dietary Quality Index-International and Dietary Phytochemical Index to affect biochemical markers among type 2 diabetic patients.","date":"2021","source":"The British journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/34167597","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41158225","id":"PMC_41158225","title":"APOA2 mediates immune therapy tolerance in hepatocellular carcinoma by inhibiting the antigen-presenting function of dendritic cells through the PPAR signaling pathway.","date":"2025","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/41158225","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41760604","id":"PMC_41760604","title":"APOA2-mediated endothelial mesenchymal transition and cancer lipid metabolism reprogramming confers antiangiogenic drug resistance through TGF-β.","date":"2026","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/41760604","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41582167","id":"PMC_41582167","title":"Predictive value of serum apolipoprotein panel (ApoA1 / ApoA2 / ApoA4) as a biomarker for individual radiosensitivity.","date":"2026","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/41582167","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.09.28.24314528","title":"Common pathogenic mechanisms for COVID-19 and differentiated thyroid cancer: a proteomic analysis","date":"2024-09-29","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.28.24314528","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.12.01.24318258","title":"Extreme MetaboHealth scores in three cohort studies associate with plasma protein markers for inflammation and cholesterol transport","date":"2024-12-02","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.01.24318258","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27477018","id":"PMC_27477018","title":"TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia.","date":"2016","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/27477018","citation_count":724,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14718574","id":"PMC_14718574","title":"The human plasma proteome: a nonredundant list developed by combination of four separate sources.","date":"2004","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/14718574","citation_count":658,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29518356","id":"PMC_29518356","title":"TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function.","date":"2018","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/29518356","citation_count":571,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"4345202","id":"PMC_4345202","title":"Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man.","date":"1973","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/4345202","citation_count":514,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12692552","id":"PMC_12692552","title":"Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12692552","citation_count":288,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"4338591","id":"PMC_4338591","title":"Amino acid sequence of human apoLp-Gln-II (apoA-II), an apolipoprotein isolated from the high-density lipoprotein complex.","date":"1972","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/4338591","citation_count":286,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11162594","id":"PMC_11162594","title":"Apolipoprotein specificity for lipid efflux by the human ABCAI transporter.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11162594","citation_count":269,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15174051","id":"PMC_15174051","title":"An investigation into the human serum \"interactome\".","date":"2004","source":"Electrophoresis","url":"https://pubmed.ncbi.nlm.nih.gov/15174051","citation_count":247,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19199708","id":"PMC_19199708","title":"Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).","date":"2009","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/19199708","citation_count":237,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21516116","id":"PMC_21516116","title":"Next-generation sequencing to generate interactome datasets.","date":"2011","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/21516116","citation_count":200,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16254078","id":"PMC_16254078","title":"Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene.","date":"2005","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16254078","citation_count":196,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"210174","id":"PMC_210174","title":"Apoprotein (E--A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction.","date":"1978","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/210174","citation_count":195,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16682745","id":"PMC_16682745","title":"Isolation and characterization of human apolipoprotein M-containing lipoproteins.","date":"2006","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16682745","citation_count":161,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3104518","id":"PMC_3104518","title":"Distribution and localization of lecithin:cholesterol acyltransferase and cholesteryl ester transfer activity in A-I-containing lipoproteins.","date":"1986","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/3104518","citation_count":153,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16710414","id":"PMC_16710414","title":"The DNA sequence and biological annotation of human chromosome 1.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16710414","citation_count":144,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23533145","id":"PMC_23533145","title":"In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.","date":"2013","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/23533145","citation_count":138,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6328445","id":"PMC_6328445","title":"Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA abundance.","date":"1984","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/6328445","citation_count":136,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23376485","id":"PMC_23376485","title":"Proteomic analysis of podocyte exosome-enriched fraction from normal human urine.","date":"2013","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/23376485","citation_count":126,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25609649","id":"PMC_25609649","title":"Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes.","date":"2015","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/25609649","citation_count":120,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17786215","id":"PMC_17786215","title":"The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/17786215","citation_count":106,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":17311,"output_tokens":1458,"usd":0.036901},"stage2":{"model":"claude-opus-4-6","input_tokens":4713,"output_tokens":1600,"usd":0.095348},"total_usd":0.354897,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":29717,"output_tokens":3196,"usd":0.068545},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":6242,"output_tokens":2861,"usd":0.154103}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"The APOA2 -265T>C (rs5082) promoter variant modulates APOA2 mRNA expression via differential DNA methylation at CpG site cg04436964 in response to saturated fat intake; CC carriers consuming a high-SFA diet show lower APOA2 expression than TT carriers, and this epigenetic difference is linked to altered tryptophan and branched-chain amino acid metabolic pathways.\",\n      \"method\": \"Epigenome-wide scan, transcription analysis, and metabolomics in three independent cohorts (BPRHS, GOLDN, FHS)\",\n      \"journal\": \"The American journal of clinical nutrition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (methylation, transcription, metabolomics) validated across three independent cohorts\",\n      \"pmids\": [\"29901700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SAMD4B increases 2'-O-methylation of APOA2 mRNA at the C-terminus, destabilizing it; decreased APOA2 protein in turn reduces PD-L1 levels through a direct interaction, thereby modulating tumor immune evasion in hepatocellular carcinoma.\",\n      \"method\": \"2'-O-methylation modification assay, multiplex immunofluorescence, single-cell RNA sequencing in PDX mouse models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct molecular mechanism demonstrated with modification assay and interaction evidence, but single lab study\",\n      \"pmids\": [\"38886351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"APOA2 mediates immune therapy resistance in hepatocellular carcinoma by impairing dendritic cell antigen presentation through the PPAR signaling pathway, and APOA2 expression is negatively correlated with MHC molecule expression.\",\n      \"method\": \"Spatial transcriptomics, single-cell RNA sequencing, hdWGCNA, CellChat ligand-receptor interaction analysis, validated with TCGA bulk RNA-seq\",\n      \"journal\": \"Translational cancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — primarily computational/transcriptomic with pathway correlation; no direct biochemical reconstitution of APOA2-PPAR interaction\",\n      \"pmids\": [\"41158225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"APOA2 overexpression in HCC upregulates TGF-β secretion, which downregulates VEGFR2 in endothelial cells (inducing endothelial-to-mesenchymal transition) and promotes fatty acid oxidation and free FA uptake in cancer cells, conferring antiangiogenic drug resistance; TGF-β inhibition abolishes these effects.\",\n      \"method\": \"Whole transcriptome sequencing of human HCC specimens, APOA2 overexpression in HCC-bearing mouse model, proteomic analysis, TGF-β inhibitor rescue experiment\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway established with in vivo overexpression, proteomics, and pharmacological inhibition rescue\",\n      \"pmids\": [\"41760604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"APOA2 is chromosomally localized to the 1q21-1q23 region of chromosome 1, confirmed by in situ hybridization and somatic cell hybrid analysis.\",\n      \"method\": \"In situ hybridisation, somatic cell hybrid DNA analysis\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct cytogenetic mapping confirmed by two independent methods\",\n      \"pmids\": [\"3136074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The APOA2 -265T>C (rs5082) promoter polymorphism interacts with dietary saturated fat intake to influence BMI and obesity risk; CC homozygotes consuming high saturated fat (≥22 g/d) show significantly higher BMI and obesity prevalence compared to T-allele carriers, with no difference at low saturated fat intake.\",\n      \"method\": \"Cross-sectional, longitudinal (20-year follow-up), and case-control analyses in three independent US populations (n=3462); gene-diet interaction analysis\",\n      \"journal\": \"Archives of internal medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — replicated across three independent populations with consistent effect; strong preponderance of evidence\",\n      \"pmids\": [\"19901143\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOA2 is a hepatically expressed apolipoprotein whose promoter variant -265T>C (rs5082) regulates its own transcription via diet-sensitive DNA methylation, such that high saturated fat intake combined with CC genotype reduces APOA2 expression and promotes obesity and altered amino acid metabolism; at the protein level, APOA2 participates in HDL metabolism and lipid transport, and in the tumor context it promotes antiangiogenic and immunotherapy resistance through TGF-β-mediated endothelial-mesenchymal transition and suppression of dendritic cell antigen presentation via PPAR signaling, while its mRNA stability is regulated by SAMD4B-mediated 2'-O-methylation that in turn modulates PD-L1 levels.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEPT papers.\n\n**Classification:**\n- Papers about APOA2 gene/protein (HDL, lipid metabolism, obesity, structure): KEEP\n- Papers about other genes that merely mention APOA2 in passing (TREM2, NDRG1, chromosome maps, large proteomics screens, MGC cDNA collections): EXCLUDE unless they contain specific mechanistic findings about APOA2 itself\n- Cattle APOA2 polymorphisms: SYMBOL COLLISION (non-ortholog organism context for body traits in bovine) — EXCLUDE for mechanism\n\n**Key KEPT papers with mechanistic content:**\n- PMID:4338591 (amino acid sequence of apoA-II)\n- PMID:210174 (apoE-A-II complex, disulfide)\n- PMID:11162594 (ABCA1 lipid efflux, apoA-II as substrate)\n- PMID:3104518 (LCAT/CET distribution in HDL subfractions with A-II)\n- PMID:16254078 (TDP-43, splicing of apoA-II exon 3)\n- PMID:6328445 (cDNA, prepro-apoAII signal/propeptide)\n- PMID:4345202 (apoC interchange between chylomicrons and HDL — mechanistic for lipid transport, mentions HDL apolipoproteins including apoA-II context)\n- PMID:29901700 (epigenomics/methylation of APOA2 promoter, SFA interaction)\n- PMID:38886351 (SAMD4B-APOA2-PD-L1 axis, 2'-O-methylation)\n- PMID:41760604 (APOA2 mediates EndoMT via TGF-β)\n- PMID:41158225 (APOA2 impairs DC antigen presentation via PPAR)\n- PMID:16682745 (apoM-containing HDL composition — mentions apoA-II as component, but no APOA2-specific mechanism)\n- PMID:14722362 (mouse Apoa2 as major QTL determinant of HDL-C)\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1972,\n      \"finding\": \"ApoA-II (apoLp-Gln-II) was isolated from human HDL and its complete amino acid sequence determined: it is composed of two identical polypeptide chains of 77 amino acids each, connected by a single disulfide bridge at position 6, with pyrrolidone carboxylic acid as the N-terminal residue and glutamine as the C-terminal residue, giving a minimum molecular weight of 17,380.\",\n      \"method\": \"Protein isolation and amino acid sequencing\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct protein isolation and complete sequence determination, foundational structural characterization\",\n      \"pmids\": [\"4338591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1978,\n      \"finding\": \"ApoA-II forms a mixed disulfide complex with apoE (apoprotein E–A-II complex) in human plasma lipoproteins; this complex was isolated and characterized, and identified in a high-density lipoprotein subfraction, demonstrating that apoA-II participates in inter-apolipoprotein disulfide bonding.\",\n      \"method\": \"Protein isolation, characterization of mixed disulfide complex, lipoprotein subfraction identification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical isolation and characterization of the disulfide complex\",\n      \"pmids\": [\"210174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"The cDNA sequence of human apoA-II was determined, revealing that prepro-apoA-II contains an 18-amino-acid signal peptide and a classical 5-amino-acid propeptide, establishing the biosynthetic precursor structure of the protein.\",\n      \"method\": \"cDNA cloning and nucleotide sequencing, mRNA abundance measurement\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct cDNA sequencing establishing prepro-protein structure\",\n      \"pmids\": [\"6328445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"LCAT mass, LCAT activity, and cholesteryl ester transfer (CET) activity in human plasma are predominantly (69–81%) associated with Lp(A-I without A-II) HDL particles rather than Lp(A-I with A-II) particles, demonstrating that the presence of apoA-II on HDL negatively influences the association of LCAT and CET activities with those particles.\",\n      \"method\": \"Immunoaffinity isolation of HDL subfractions, gel filtration, activity assays for LCAT and CET\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct biochemical fractionation with functional activity measurements in multiple subjects\",\n      \"pmids\": [\"3104518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ABCA1 mediates cholesterol and phospholipid efflux using apoA-II as an acceptor apolipoprotein; apoA-II binds to ABCA1-expressing cells with a Kd of 0.58 µg/mL (similar affinity to apoA-I), demonstrating that ABCA1-mediated lipid efflux and apolipoprotein binding is not specific to apoA-I but extends to apoA-II and other exchangeable apolipoproteins containing amphipathic helical domains.\",\n      \"method\": \"Stably transfected HeLa cells expressing ABCA1-GFP, cholesterol and phospholipid efflux assays, specific binding assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro reconstitution in transfected cells with binding constants and efflux quantification\",\n      \"pmids\": [\"11162594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TDP-43 binds the (GU)16 repeat tract at the intron 2/exon 3 junction of the APOA2 pre-mRNA and acts as a splicing silencer; depletion of TDP-43 by siRNA renders exon 3 inclusion constitutive, overriding the need for exonic (ASF/SF2, SC35-dependent ESE) and intronic (SRp40/SRp55-dependent) splicing enhancers. Additionally, hnRNPH1 binds a G-rich element in intron 2 to inhibit exon 3 splicing, while SRp40 and SRp55 bind a purine-rich region in intron 3 to promote inclusion.\",\n      \"method\": \"siRNA knockdown of TDP-43, in vitro splicing assays, UV cross-linking/immunoprecipitation, mutagenesis of cis-elements\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — siRNA knockdown with constitutive splicing phenotype, multiple orthogonal methods including mutagenesis and factor-binding assays\",\n      \"pmids\": [\"16254078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The APOA2 -265T>C (rs5082) promoter polymorphism interacts with saturated fatty acid (SFA) intake to alter DNA methylation at CpG site cg04436964 in the APOA2 regulatory region; CC genotype carriers on a high-SFA diet show differential methylation at this site compared to TT carriers, and this is negatively correlated with APOA2 mRNA expression. CC carriers consuming high-SFA had lower APOA2 expression than TT carriers. Metabolomic analysis linked these genotype-specific methylation differences to alterations in tryptophan and branched-chain amino acid (BCAA) metabolic pathways.\",\n      \"method\": \"Epigenome-wide scan (DNA methylation), transcriptomic analysis of APOA2 mRNA, metabolomics, validated in three independent cohorts\",\n      \"journal\": \"The American journal of clinical nutrition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (methylation, transcriptomics, metabolomics) replicated across three independent cohorts\",\n      \"pmids\": [\"29901700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SAMD4B suppresses APOA2 mRNA stability via 2'-O-methylation modification at the C-terminus of APOA2 mRNA; reduced APOA2 protein levels resulting from this modification lead to decreased PD-L1 expression through a direct APOA2–PD-L1 interaction, thereby improving the tumor immune microenvironment in hepatocellular carcinoma.\",\n      \"method\": \"2'-O-methylation modification assay, multiplex immunofluorescence, single-cell RNA sequencing in PDX mouse models, protein interaction assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — novel epitranscriptomic mechanism with multiple supporting methods but single lab, complex multi-component pathway\",\n      \"pmids\": [\"38886351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"APOA2 impairs dendritic cell antigen presentation through the PPAR signaling pathway, contributing to an immunosuppressive tumor microenvironment in hepatocellular carcinoma; APOA2 expression was negatively correlated with MHC molecule expression on dendritic cells.\",\n      \"method\": \"Spatial transcriptomics, single-cell RNA sequencing, hdWGCNA, CellChat ligand-receptor interaction analysis, TCGA validation\",\n      \"journal\": \"Translational cancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3–4 — computational/transcriptomic analysis, no direct in vitro or in vivo functional validation of APOA2 acting on DCs\",\n      \"pmids\": [\"41158225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"APOA2 overexpression in hepatocellular carcinoma cells promotes antiangiogenic drug resistance by upregulating TGF-β secretion; TGF-β in turn reduces VEGFR2 expression and induces endothelial-to-mesenchymal transition (EndoMT) in vascular endothelial cells, while simultaneously initiating fatty acid oxidation and increased free fatty acid uptake in cancer cells to stimulate proliferation. Pharmacological inhibition of TGF-β eliminated APOA2-mediated EndoMT and lipid metabolic reprogramming.\",\n      \"method\": \"APOA2 overexpression in HCC mouse models, whole transcriptome sequencing, proteomic analysis, TGF-β inhibition experiments\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo mouse model with overexpression, proteomic validation, and pharmacological rescue experiment\",\n      \"pmids\": [\"41760604\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOA2 encodes a homodimeric HDL apolipoprotein (two 77-aa chains linked by a disulfide at position 6, synthesized as a prepro-protein with signal and propeptide sequences) that acts as an ABCA1 lipid-efflux acceptor, forms mixed disulfides with apoE on HDL, inhibits LCAT and cholesteryl ester transfer activity on HDL particles, and undergoes TDP-43-dependent pre-mRNA splicing regulation; its promoter methylation and expression are modulated by saturated fat intake in a genotype-dependent manner, and emerging evidence indicates APOA2 protein participates in TGF-β-mediated endothelial-mesenchymal transition and lipid metabolic reprogramming in cancer contexts.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"APOA2 encodes an apolipoprotein that functions in HDL metabolism and lipid transport, with expression regulated by a promoter variant (-265T>C, rs5082) that modulates DNA methylation at CpG site cg04436964 in a saturated fat–dependent manner; CC homozygotes consuming high saturated fat exhibit reduced APOA2 transcription, higher BMI, and altered tryptophan and branched-chain amino acid metabolism [PMID:29901700, PMID:19901143]. APOA2 mRNA stability is further regulated by SAMD4B-mediated 2'-O-methylation at its C-terminal coding region, and decreased APOA2 protein reduces PD-L1 levels through a direct interaction, modulating tumor immune evasion in hepatocellular carcinoma [PMID:38886351]. In HCC, APOA2 overexpression upregulates TGF-β secretion, which drives endothelial-to-mesenchymal transition by downregulating VEGFR2 in endothelial cells and promotes fatty acid oxidation in cancer cells, conferring resistance to antiangiogenic therapy [PMID:41760604].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Establishing the chromosomal location of APOA2 at 1q21–q23 provided the first physical framework for studying its genetic regulation and linkage to metabolic traits.\",\n      \"evidence\": \"In situ hybridization and somatic cell hybrid DNA analysis\",\n      \"pmids\": [\"3136074\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No functional regulatory elements identified at this stage\", \"Relationship between locus and metabolic phenotypes not yet explored\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The discovery that the -265T>C promoter polymorphism interacts with dietary saturated fat to influence BMI and obesity risk established APOA2 as a gene-diet interaction locus, revealing that its regulation is environmentally conditional.\",\n      \"evidence\": \"Cross-sectional, longitudinal, and case-control analyses across three independent US populations (n=3462)\",\n      \"pmids\": [\"19901143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking genotype to obesity phenotype was unknown\", \"Whether the polymorphism altered APOA2 transcription or downstream pathways was unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identification of CpG methylation at cg04436964 as the mediator between the -265T>C variant, saturated fat intake, and APOA2 expression resolved the epigenetic mechanism underlying the gene-diet interaction and linked it to altered amino acid metabolism.\",\n      \"evidence\": \"Epigenome-wide association, transcription analysis, and metabolomics across three cohorts (BPRHS, GOLDN, FHS)\",\n      \"pmids\": [\"29901700\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal direction between methylation change and metabolite alterations not formally tested\", \"Whether dietary intervention reverses methylation and expression changes is untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that SAMD4B destabilizes APOA2 mRNA via 2'-O-methylation and that reduced APOA2 protein directly decreases PD-L1 levels established a post-transcriptional regulatory axis linking APOA2 to tumor immune evasion in hepatocellular carcinoma.\",\n      \"evidence\": \"2'-O-methylation modification assay, multiplex immunofluorescence, single-cell RNA sequencing in PDX mouse models\",\n      \"pmids\": [\"38886351\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of the APOA2–PD-L1 interaction is undefined\", \"Single-laboratory finding not yet independently replicated\", \"Whether this mechanism operates outside HCC is unknown\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Demonstration that APOA2 overexpression drives antiangiogenic resistance through TGF-β–mediated endothelial-to-mesenchymal transition and metabolic reprogramming provided a mechanistic basis for APOA2's tumor-promoting role beyond immune modulation.\",\n      \"evidence\": \"APOA2 overexpression in HCC-bearing mouse model, whole transcriptome sequencing, proteomic analysis, and TGF-β inhibitor rescue experiment\",\n      \"pmids\": [\"41760604\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether APOA2 directly activates TGF-β transcription or acts through an intermediate is unresolved\", \"Relevance to non-HCC tumors not tested\", \"Interaction between the TGF-β axis and the PD-L1 axis described in other studies is unexplored\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How APOA2's canonical role in HDL metabolism relates mechanistically to its emerging tumor-microenvironment functions — and whether its lipid-binding properties directly mediate TGF-β signaling or PPAR pathway modulation — remains uncharacterized.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural or biophysical characterization of APOA2's interaction with PD-L1 or TGF-β pathway components\", \"In vivo validation of the PPAR-dependent dendritic cell suppression mechanism is lacking\", \"Whether the diet-epigenetic regulatory axis at -265T>C influences APOA2's tumor-associated functions is completely unexplored\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"SAMD4B\",\n      \"CD274\",\n      \"TGFB1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Apolipoprotein A-II is the second most abundant protein of high-density lipoproteins, synthesized as a prepro-protein (18-aa signal peptide plus 5-aa propeptide) that matures into a homodimer of two 77-residue chains linked by a Cys-6 disulfide bridge [PMID:4338591, PMID:6328445]. On HDL particles, apoA-II forms mixed disulfide complexes with apoE [PMID:210174], serves as an acceptor for ABCA1-mediated cholesterol and phospholipid efflux with nanomolar-range binding affinity [PMID:11162594], and restricts the association of LCAT and cholesteryl ester transfer activities to apoA-II-containing particles [PMID:3104518]. APOA2 pre-mRNA splicing is regulated by TDP-43, which silences exon 3 inclusion by binding a (GU)₁₆ intronic element, while promoter methylation at the -265T>C polymorphism modulates APOA2 expression in a saturated-fat-intake-dependent manner [PMID:16254078, PMID:29901700]. In hepatocellular carcinoma, APOA2 overexpression drives TGF-β-dependent endothelial-mesenchymal transition, lipid metabolic reprogramming, and antiangiogenic drug resistance, and APOA2 protein interacts with PD-L1 to modulate the tumor immune microenvironment [PMID:41760604, PMID:38886351].\",\n  \"teleology\": [\n    {\n      \"year\": 1972,\n      \"claim\": \"Determining the primary structure of apoA-II established it as a disulfide-linked homodimer of 77-residue chains, defining the fundamental architecture of the second major HDL apolipoprotein.\",\n      \"evidence\": \"Protein isolation from human HDL and complete amino acid sequencing\",\n      \"pmids\": [\"4338591\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No three-dimensional structure determined\",\n        \"Lipid-binding mechanism and amphipathic helix arrangement unresolved\",\n        \"Biological function of the disulfide linkage unknown\"\n      ]\n    },\n    {\n      \"year\": 1978,\n      \"claim\": \"Discovery of a mixed apoE–apoA-II disulfide complex in plasma lipoproteins revealed that apoA-II participates in inter-apolipoprotein covalent interactions, suggesting it modulates HDL composition beyond simple structural scaffolding.\",\n      \"evidence\": \"Biochemical isolation and characterization of the disulfide complex from human plasma HDL subfractions\",\n      \"pmids\": [\"210174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Functional consequence of apoE–apoA-II complex formation on lipoprotein metabolism unknown\",\n        \"Stoichiometry and regulation of complex formation not defined\"\n      ]\n    },\n    {\n      \"year\": 1984,\n      \"claim\": \"cDNA cloning revealed that apoA-II is synthesized as a prepro-protein with an 18-aa signal peptide and a 5-aa propeptide, establishing its secretory biosynthetic pathway.\",\n      \"evidence\": \"cDNA cloning and nucleotide sequencing of human APOA2\",\n      \"pmids\": [\"6328445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Propeptide cleavage protease not identified\",\n        \"Tissue-specific regulation of APOA2 transcription not characterized\"\n      ]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Demonstration that LCAT and cholesteryl ester transfer activities preferentially associate with apoA-I-only HDL particles established apoA-II as a negative modulator of HDL cholesterol esterification and transfer, clarifying a long-debated functional distinction between HDL subclasses.\",\n      \"evidence\": \"Immunoaffinity fractionation of HDL subpopulations with LCAT and CET activity assays in human plasma\",\n      \"pmids\": [\"3104518\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct molecular mechanism by which apoA-II excludes LCAT/CET activity not elucidated\",\n        \"In vivo metabolic consequences of altered LCAT partitioning not tested\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showing that apoA-II binds ABCA1 with affinity comparable to apoA-I and mediates cholesterol/phospholipid efflux broadened the understanding of ABCA1 beyond apoA-I, positioning apoA-II as a physiological lipid acceptor in reverse cholesterol transport.\",\n      \"evidence\": \"Cholesterol and phospholipid efflux assays and specific binding measurements in ABCA1-GFP-transfected HeLa cells\",\n      \"pmids\": [\"11162594\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Relative in vivo contribution of apoA-II versus apoA-I to ABCA1-mediated efflux not quantified\",\n        \"Whether apoA-II-containing nascent HDL particles have distinct downstream fates is unknown\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identification of TDP-43 as a splicing silencer of APOA2 exon 3 uncovered a post-transcriptional control layer for apoA-II expression, showing that a ubiquitous RNA-binding protein governs alternative splicing of this liver-expressed gene.\",\n      \"evidence\": \"siRNA knockdown of TDP-43, in vitro splicing, UV cross-linking/immunoprecipitation, and cis-element mutagenesis\",\n      \"pmids\": [\"16254078\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Physiological signals that modulate TDP-43's splicing activity on APOA2 not identified\",\n        \"Consequences of exon 3 inclusion/skipping on apoA-II protein function not characterized\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating that the -265T>C promoter polymorphism interacts with saturated fat intake to alter CpG methylation and APOA2 expression provided a gene-environment epigenetic mechanism for inter-individual variation in apoA-II levels.\",\n      \"evidence\": \"Epigenome-wide methylation, transcriptomic, and metabolomic analyses replicated across three independent cohorts\",\n      \"pmids\": [\"29901700\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Causal direction of methylation–expression relationship not established by intervention\",\n        \"How altered apoA-II levels translate to downstream changes in tryptophan and BCAA metabolism is mechanistically undefined\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that SAMD4B destabilizes APOA2 mRNA via 2'-O-methylation and that reduced apoA-II decreases PD-L1 through a direct protein interaction revealed an unexpected immunoregulatory role for apoA-II in the tumor microenvironment.\",\n      \"evidence\": \"2'-O-methylation assays, multiplex immunofluorescence, single-cell RNA-seq in PDX mouse models, and protein interaction assays in hepatocellular carcinoma\",\n      \"pmids\": [\"38886351\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct apoA-II–PD-L1 binding interface not structurally characterized\",\n        \"Specificity of the 2'-O-methylation mechanism to APOA2 versus other mRNAs not assessed\",\n        \"Independent replication in a second laboratory pending\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Computational spatial transcriptomics linked APOA2 to impaired dendritic cell antigen presentation via PPAR signaling in HCC, but this remains a correlative observation without direct functional validation.\",\n      \"evidence\": \"Spatial transcriptomics, single-cell RNA-seq, hdWGCNA, and CellChat analysis in hepatocellular carcinoma tissues\",\n      \"pmids\": [\"41158225\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No in vitro or in vivo functional experiment directly testing apoA-II's effect on dendritic cell MHC expression\",\n        \"PPAR pathway link is inferred computationally without pharmacological or genetic perturbation\",\n        \"Single study without independent cohort replication\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"In vivo overexpression showed that apoA-II drives antiangiogenic drug resistance in HCC by upregulating TGF-β, which induces endothelial-mesenchymal transition and lipid metabolic reprogramming, and TGF-β inhibition reverses these effects.\",\n      \"evidence\": \"APOA2 overexpression in mouse HCC models with whole transcriptome sequencing, proteomics, and pharmacological TGF-β inhibition\",\n      \"pmids\": [\"41760604\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which apoA-II upregulates TGF-β secretion is unknown\",\n        \"Whether this cancer-context role reflects a physiological function of apoA-II in non-malignant tissue is untested\",\n        \"Confirmation in patient-derived models or clinical samples needed\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis by which apoA-II modulates LCAT and CET activity on HDL, the physiological significance of the apoE–apoA-II disulfide complex, and whether apoA-II's newly described immunomodulatory and TGF-β-related activities in cancer operate through the same lipid-binding surfaces used in lipoprotein metabolism remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No high-resolution structure of lipid-bound apoA-II dimer\",\n        \"Relative in vivo contribution of apoA-II to reverse cholesterol transport versus apoA-I not quantified\",\n        \"Mechanistic link between apoA-II's lipid-binding properties and its cancer-associated signaling roles undefined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 3, 4]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 4, 6]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"complexes\": [\n      \"HDL particle\",\n      \"apoE-apoA-II disulfide complex\"\n    ],\n    \"partners\": [\n      \"APOE\",\n      \"ABCA1\",\n      \"TARDBP\",\n      \"PD-L1\",\n      \"TGFB1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}